Back to 
Centiva Capital, LP
Centiva Capital, LP
IBRX
Showing 0 of 4 quarters
Position history for Centiva Capital, LP's holdings in IMMUNITYBIO INC
No. Centiva Capital exited its IBRX (Immunitybio) position in Q2 2023. Its Q1 2023 13F listed 51,692 shares worth $94,080. Centiva Capital first reported IBRX in Q2 2022 and held it in 2 quarterly 13F filings.
Current Value
—
Current Shares
—
Total Value Change
$0
Total Shares Change
0
No position history available for this security.